


2nd RePo-SUDOE Conference Programme

📍 December 15th, 2025 📍 Hotel Finisterre, A Coruña

9:00 h - 9:30 h	Arrival of participants and registration
9:30h - 9:45 h	Opening Ceremony
9:45 h - 11:30 h	Keynote session 1: Drug Resistance • Drug Resistance in Cancer - Philippe Pourquier - PharmD PhD at Montpellier Cancer Research Institute • The Importance of Correct Dosing - Christian Franken - Head of Central Pharmacy at GFO and Assistant Professor at Maastricht University • Testing Resistance: Diagnostic Biomarkers and Pharmacogenomics - Robert Loewe - CEO and Founder of GeneSurge, Work package Lead for Patient Stratification at REPO4EU
11:30 h - 12:15 h	Coffee Break Networking
12:15 h - 14:00 h	Keynote session 2: Drug Repurposing • Multi-omics Data Integration to Explain Biological Processes - Ana Conesa Cegarra - Research professor at CSIC, and leader of the Genomics of Gene Regulation Lab at I2SysBio (CSIC-UV) • Repurposing drugs through network medicine and artificial intelligence - Lucía Prieto Santamaría - Assistant Professor at Universidad Politécnica de Madrid (UPM) • From Cellular Mechanisms to Novel Therapies in Knee Osteoarthritis - Beatriz Caramés Pérez - Cartilage Biology Group Leader - Instituto de Investigación Biomédica de A Coruña (INIBIC)
14:00 h - 15:30 h	Lunch
15:30 h - 16:30 h	Roundtable
16:30 h - 18:00 h	Demos & Closing Remarks

Meet our speakers!

Dr Philippe Pourquier - PharmD, PhD, Montpellier Cancer Research Institute (INSERM)



Dr Philippe Pourquier is a **Research Director at INSERM U1194 within the Montpellier Cancer Research Institute (France)**. His research focuses on understanding the **mechanisms of action and resistance** to antitumor agents, particularly topoisomerase inhibitors and other **DNA-damaging drugs**. His goal is to **identify predictive biomarkers** to overcome treatment resistance and optimize patient selection for targeted therapies.

He holds a **PharmD and a PhD from the University of Bordeaux** and completed his postdoctoral training at the **National Cancer Institute (NCI/NIH, USA)**. Dr Pourquier has authored over 90 peer-reviewed publications, including in *Nature Medicine* and *Nature Chemistry*, and currently serves as **President of the French Cancer Society** and of the **Scientific Council of the Regional League Against Cancer**.

Dr Christian Franken, Head of Central Pharmacy at GFO and Assistant Professor at Maastricht University



Dr Christian Franken holds a **PhD in Pharmacology from the University of Bonn** and is a **specialist in hospital pharmacy**. He has held senior positions at the University Hospitals of Düsseldorf, Ulm, and Aachen, gaining extensive experience in **clinical pharmacy management**.

In 2018, he **co-founded DIHESYS (Digital Health Systems GmbH)**, a company dedicated to digital drug printing technologies. He currently directs the Central Pharmacy of GFO, overseeing the supply of medicines and medical devices, while teaching at Apollon University of Health Economics and the universities of Jena and Basel. His work bridges **technological innovation and advanced pharmaceutical care**.

Dr Robert Loewe, CEO and Founder of GeneSurge, Work package Lead for Patient Stratification at REPO4EU



Dr Robert Loewe has over **20 years of experience in oncology diagnostics and pharmacogenomics**. He began his career at **CellControl**, studying tumor chemosensitivity, and later joined **Roche Pharma and Roche Diagnostics**, focusing on **early cancer detection, companion diagnostics, and therapy prediction**.

He has collaborated with **Novartis and Takeda** on biomarker and patient stratification studies. As **CEO of GeneSurge**, he leads efforts to **personalize diagnostics and optimize treatments**, aiming to bring precision medicine into real-world clinical practice.

Meet our speakers!

Dr Ana Conesa Cegarra, Research professor at CSIC, and leader of the Genomics of Gene Regulation Lab at I2SysBio (CSIC-UV)



Dr Ana Conesa is a **Research Professor at the Spanish National Research Council (CSIC)** and leads the **Genomics of Gene Regulation Laboratory at the Institute for Integrative Systems Biology (I2SysBio, CSIC-University of Valencia)**. Her research develops bioinformatics methods for multi-omics data integration and the functional regulation of genes.

She is the creator of widely used bioinformatics tools such as **Blast2GO** and **SQANTI**, recognized internationally within the genomics community. Dr Conesa has been named a **Fellow of the International Society for Computational Biology (ISCB)** and is a member of the **Royal Academy of Engineering of Spain**. She is also co-founder of the bioinformatics company Biobam.

Dr Lucía Prieto Santamaría, Assistant Professor at Universidad Politécnica de Madrid



Dr Lucía Prieto is a **researcher at the Medical Data Analytics Laboratory** of the **Center for Biomedical Technology (CTB-UPM)**. She holds a **PhD in Software, Systems and Computing**, and her work combines artificial intelligence and network medicine to identify new therapeutic uses for existing drugs.

She received the **Extraordinary Doctorate Award** (UPM) and the **Francisco del Pozo Award** (CTB) for her innovative research on large-scale biomedical data analysis. Dr. Prieto completed a research stay in Prof. Albert-László Barabási's lab (Northeastern University, USA) and serves as reviewer, editor, and committee member in international scientific organizations. She is also part of the executive board of the **Spanish Society for Artificial Intelligence in Biomedicine (IABiomed)**.

Dr Beatriz Caramés Pérez, Principal Investigator at Instituto de Investigación Biomédica de A Coruña (INIBIC)



Dr Beatriz Caramés leads the **Cartilage Biology Unit at the Institute of Biomedical Research of A Coruña (INIBIC)**. Her research explores **molecular and cellular mechanisms** underlying **joint aging and osteoarthritis (OA)** to develop novel targeted therapies.

She has directed **national and international projects** advancing into clinical studies in OA patients and collaborates with the **pharmaceutical industry through public-private partnerships**. Dr Caramés also participates in **European consortia** focused on innovative therapeutic strategies for joint degeneration and regenerative medicine.